SPX3,825.33+39.95 1.06%
DIA310.85+3.03 0.98%
IXIC11,127.85+99.11 0.90%

Drug developer Zymeworks adopts 'poison pill' to keep All Blue at bay

reuters.com · 06/10/2022 09:55
Drug developer Zymeworks adopts 'poison pill' to keep All Blue at bay

- Cancer therapy developer Zymeworks Inc ZYME said on Friday it had adopted a "poison pill" to thwart a hostile takeover from All Blue Capital, a month after rejecting the investment firm's $773 million bid on valuation grounds.

Vancouver, Canada-based Zymeworks said the shareholder rights plan would stop investors from amassing more than 10% of its share, or 20% in the case of some passive investors.

Poison pills, such as the one recently adopted by Twitter Inc TWTR before it accepted Elon Musk's buyout bid, make a takeover more difficult by allowing existing shareholders to buy shares at a discount, diluting a suitor's ownership stake.

In a filing late last month, All Blue Falcons raised its stake in Zymeworks to 6.9%.

The rights plan will expire in June next year.


(Reporting by Manas Mishra in Bengaluru; Editing by Anil D'Silva)

((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manaswrites15;))